CClinicalTrials.gg
CompletedNCT05039697NBOLUpdated Feb 19, 2025

Normobaric Hyperoxia Combined with Endovascular Therapy in Patients with Stroke Within 6 Hours of Onset:longterm Outcome

An interventional study of oxygen in Stroke, Acute, Hypoxia-Ischemia, Brain and ENDOVASCULAR TREATMENT, sponsored by Capital Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Capital Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The overall incidence of good outcome for AIS following endovascular treatment is only proximately 50%. Whether NBO was safe and effective to improve acute ischemic stroke prognosis is still unclear. The investigators' hypothesis is thatNBO is a safe and effective strategy to improve longterm outcome in AIS patients undergoing endovascular treatment.

Read the detailed description

NBO therapy is to deliver high flow oxygen (10L/min) through an oxygen storage mask. This treatment should be started in the emergency room immediately after the patient is randomized into the group, and oxygen should be continued for 4 hours.

In previous clinical studies of NBO, patients who have not receive revascularization often choose NBO for 8 hours, and studies have concluded that oxygen inhalation for more than 10 hours may bring about the risk of oxygen poisoning. However, a too short treatment time may not bring benefits. Secondly, ideally, we want to ensure that stroke patients receive NBO treatment before achieving reperfusion to protect the ischemic brain tissue, and add 1-2 hours after reperfusion. In the clinical environment after the patient arrives in the emergency department, it takes 2-3 hours to complete the revascularization process. Therefore, we believe that 4 hours of oxygen inhalation is reasonable. And our single-center study also supports that NBO treatment for 4 hours is beneficial.

The specific content is as follows: In the emergency room, patients who are assessed for suspected large blood vessels of acute anterior circulation will be randomized after signing the informed consent. If the subject is randomly divided into NBO+ET group, by putting the patient on Oxygen mask, and then immediately give oxygen (10L/min). NBO treatment is no later than half an hour after randomization. Oxygen comes from the hospital's oxygen center and is transported through wall pipes (oxygen concentration: 100%). The oxygen mask and the wall oxygen are connected by a 1.5 meter long oxygen pipe. When the patient is transferred to the operating room, we provide oxygen through a portable oxygen cylinder (capacity: 4L). In addition, in the operating room and intensive care unit, patients continue to be given wall oxygen therapy until the oxygen inhalation lasts for 4 hours. The arterial blood gas was drawn after 4 hours of oxygen inhalation. The control group directly inhales room air through the patient's nasal cavity without using any equipment. At the same time, patients in the control group were also drawn blood gas analysis at corresponding time points (approximately 4 hours after randomization).

02

Conditions studied

  • Stroke, Acute
  • Hypoxia-Ischemia, Brain
  • ENDOVASCULAR TREATMENT
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥ 18 years old.
  • The clinical symptoms and signs are consistent with acute anterior circulation large vessel occlusion;
  • NIHSS score ≥ 10 points;
  • (Level of consciousness) NIHSS score 0 or 1;
  • The time from onset to randomization is within 6 hours of onset;
  • The mRS score before stroke is 0-1;
  • The patient has good compliance and can complete the operation with local anesthesia;
  • The patient can cooperate with this study and follow-up in the future
  • Patient and family members sign informed consent。-

Exclusion criteria

Exclusion Criteria:

  • Rapid neurological function improvement, NIHSS score less than 10 points, or evidence of vessel recanalization prior to randomization;
  • Seizures at stroke onset;
  • Intracranial hemorrhage;
  • Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal;
  • Platelet count of less than 100,000 per cubic millimeter;
  • Severe hepatic or renal dysfunction;
  • Active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;
  • >3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2) 95% as per current stroke management guidelines;
  • Medically unstable;
  • Life expectancy\<90 days;
  • Evidence of intracranial tumor;
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
282 participants (actual)

Study arms

  • Experimental
    NBO group Normobaric Hyperoxia combined with endovascular mechanical thrombectomy

    Within 6 hours after stroke onset, patients were randomized into the NBO group and immediately given 100% oxygen inhalation (no more than 30minutes after admission) at a ventilation rate of 10L/min using a sealed non-ventilating oxygen storagemask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain ventilation, the FiO2 should be set to 1.0.

    Other: oxygen

  • Placebo comparator
    Control group Inhale air placebo plus endovascular mechanical thrombectomy

    For Sham NBO group, Patients were immediately given oxygen inhalation (no more than 30 minutes after admission) at a ventilation rate of 1l/min using the same mask and keep giving oxygen for 4 hours. If the patient needs to be intubated with a ventilator to maintain, the FiO2 should be set to 0.3 and gradualy incerased if spO2≤94%

    Other: oxygen

Interventions

  • Otheroxygen

    deliver high flow oxygen (10L/min)

05

What researchers measure

Primary outcomes

  1. Modified Rankin Scale

    the mRs is an ordinal disability score of 7 categories (0=no symptoms to 5=severe disability,and 6=death)

    Time frame: 1 year ± 30 days after randomization

Secondary outcomes

  1. EuroQol- 5 Dimension (EQ-5D)

    EuroQol five dimensions questionnaire (EQ-5D)EQ-5D is an instrument which evaluates the generic quality of life developed in Europe and widely used. The EQ-5D descriptive system is a preference-based HRQL measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

    Time frame: 1 year ± 30 days after randomization

  2. The proportion of good prognosis

    the mRs is an ordinal disability score of 7 categories (0 = no symptoms to 5 = severe disability, and 6 = death);The ratio of 0 to 2

    Time frame: 1 year ± 30 days after randomization

  3. Functional independence

    The Proportion of mRS 0-1

    Time frame: 1 year ± 30 days after randomization

  4. The Proportion of mRS 0-3

    secondary clinical efficacy endpoint

    Time frame: 1 year ± 30 days after randomization

  5. Barthel Index (BI)

    he BI is an ordinal disability score of 10 categories(range from 0 to 100, higher values indicate better prognosis);

    Time frame: 1 year ± 30 days after randomization

  6. All-cause mortality

    clinical safety endpoint;

    Time frame: 1 year ± 30 days after randomization

  7. New major vascular events

    clinical safety endpoint; Major vascular events include fatal or nonfatal cardiac events, fatal or nonfatal stroke, or fatal or nonfatal major peripheral arterial or thrombo-embolic events.

    Time frame: 1 year ± 30 days after randomization

  8. kaplan-meier curve

    clinical efficacy endpoint

    Time frame: 1 year ± 30 days after randomization

06

Study locations

1 site
  • Baojun Hou
    Beijing, Beijing 100053, China
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05039697
Lead sponsor
Capital Medical University
Responsible party
Ji Xunming,MD,PhD (Principal Investigator, Capital Medical University) — Principal investigator
First posted
Sep 9, 2021
Start date
Apr 22, 2021
Primary completion
Feb 4, 2024
Completion
Feb 4, 2024
Last update
Feb 19, 2025

Study contacts

Xunming Ji, MD
study chair · Xuan Wu Hospital#Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion